Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19
Two proteases produced by the SARS-CoV-2 virus, the main protease and papain-like protease, are essential for viral replication and have become the focus of drug development programs for treatment of COVID-19. We screened a highly focused library of compounds containing covalent warheads designed to...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 11, 2021
|
| In: |
ACS infectious diseases
Year: 2021, Jahrgang: 7, Heft: 6, Pages: 1457-1468 |
| ISSN: | 2373-8227 |
| DOI: | 10.1021/acsinfecdis.0c00815 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1021/acsinfecdis.0c00815
|
| Verfasserangaben: | Kas Steuten, Heeyoung Kim, John C. Widen, Brett M. Babin, Ouma Onguka, Scott Lovell, Oguz Bolgi, Berati Cerikan, Christopher J. Neufeldt, Mirko Cortese, Ryan K. Muir, John M. Bennett, Ruth Geiss-Friedlander, Christoph Peters, Ralf Bartenschlager, and Matthew Bogyo |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1766788823 | ||
| 003 | DE-627 | ||
| 005 | 20230427034930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210813s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsinfecdis.0c00815 |2 doi | |
| 035 | |a (DE-627)1766788823 | ||
| 035 | |a (DE-599)KXP1766788823 | ||
| 035 | |a (OCoLC)1341420623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Steuten, Kas |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 |c Kas Steuten, Heeyoung Kim, John C. Widen, Brett M. Babin, Ouma Onguka, Scott Lovell, Oguz Bolgi, Berati Cerikan, Christopher J. Neufeldt, Mirko Cortese, Ryan K. Muir, John M. Bennett, Ruth Geiss-Friedlander, Christoph Peters, Ralf Bartenschlager, and Matthew Bogyo |
| 264 | 1 | |c February 11, 2021 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.08.2021 | ||
| 520 | |a Two proteases produced by the SARS-CoV-2 virus, the main protease and papain-like protease, are essential for viral replication and have become the focus of drug development programs for treatment of COVID-19. We screened a highly focused library of compounds containing covalent warheads designed to target cysteine proteases to identify new lead scaffolds for both Mpro and PLpro proteases. These efforts identified a small number of hits for the Mpro protease and no viable hits for the PLpro protease. Of the Mpro hits identified as inhibitors of the purified recombinant protease, only two compounds inhibited viral infectivity in cellular infection assays. However, we observed a substantial drop in antiviral potency upon expression of TMPRSS2, a transmembrane serine protease that acts in an alternative viral entry pathway to the lysosomal cathepsins. This loss of potency is explained by the fact that our lead Mpro inhibitors are also potent inhibitors of host cell cysteine cathepsins. To determine if this is a general property of Mpro inhibitors, we evaluated several recently reported compounds and found that they are also effective inhibitors of purified human cathepsins L and B and showed similar loss in activity in cells expressing TMPRSS2. Our results highlight the challenges of targeting Mpro and PLpro proteases and demonstrate the need to carefully assess selectivity of SARS-CoV-2 protease inhibitors to prevent clinical advancement of compounds that function through inhibition of a redundant viral entry pathway. | ||
| 700 | 1 | |a Kim, Heeyoung |e VerfasserIn |0 (DE-588)1233743139 |0 (DE-627)1758143819 |4 aut | |
| 700 | 1 | |a Widen, John C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Babin, Brett M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Onguka, Ouma |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lovell, Scott |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bolgi, Oguz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cerikan, Berati |e VerfasserIn |0 (DE-588)1126652776 |0 (DE-627)881234761 |0 (DE-576)484627627 |4 aut | |
| 700 | 1 | |a Neufeldt, Christopher |e VerfasserIn |0 (DE-588)113060795X |0 (DE-627)88481954X |0 (DE-576)486862925 |4 aut | |
| 700 | 1 | |a Cortese, Mirko |e VerfasserIn |0 (DE-588)1073720225 |0 (DE-627)829364609 |0 (DE-576)435287699 |4 aut | |
| 700 | 1 | |a Muir, Ryan K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bennett, John M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geiss-Friedlander, Ruth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peters, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bartenschlager, Ralf |d 1958- |e VerfasserIn |0 (DE-588)1058097989 |0 (DE-627)796390509 |0 (DE-576)168706067 |4 aut | |
| 700 | 1 | |a Bogyo, Matthew |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American Chemical Society |t ACS infectious diseases |d Washington, DC : ACS Publ., 2015 |g 7(2021), 6, Seite 1457-1468 |h Online-Ressource |w (DE-627)815910479 |w (DE-600)2806068-4 |w (DE-576)425055914 |x 2373-8227 |7 nnas |
| 773 | 1 | 8 | |g volume:7 |g year:2021 |g number:6 |g pages:1457-1468 |g extent:12 |a Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 |
| 856 | 4 | 0 | |u https://doi.org/10.1021/acsinfecdis.0c00815 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210813 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1058097989 |a Bartenschlager, Ralf |m 1058097989:Bartenschlager, Ralf |d 910000 |d 911700 |e 910000PB1058097989 |e 911700PB1058097989 |k 0/910000/ |k 1/910000/911700/ |p 15 | ||
| 998 | |g 1073720225 |a Cortese, Mirko |m 1073720225:Cortese, Mirko |d 910000 |d 911700 |e 910000PC1073720225 |e 911700PC1073720225 |k 0/910000/ |k 1/910000/911700/ |p 9 | ||
| 998 | |g 113060795X |a Neufeldt, Christopher |m 113060795X:Neufeldt, Christopher |d 910000 |d 911700 |e 910000PN113060795X |e 911700PN113060795X |k 0/910000/ |k 1/910000/911700/ |p 8 | ||
| 998 | |g 1126652776 |a Cerikan, Berati |m 1126652776:Cerikan, Berati |d 910000 |d 911700 |e 910000PC1126652776 |e 911700PC1126652776 |k 0/910000/ |k 1/910000/911700/ |p 7 | ||
| 998 | |g 1233743139 |a Kim, Heeyoung |m 1233743139:Kim, Heeyoung |d 910000 |d 911700 |e 910000PK1233743139 |e 911700PK1233743139 |k 0/910000/ |k 1/910000/911700/ |p 1 |x j | ||
| 999 | |a KXP-PPN1766788823 |e 3967970604 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Kas Steuten, Heeyoung Kim, John C. Widen, Brett M. Babin, Ouma Onguka, Scott Lovell, Oguz Bolgi, Berati Cerikan, Christopher J. Neufeldt, Mirko Cortese, Ryan K. Muir, John M. Bennett, Ruth Geiss-Friedlander, Christoph Peters, Ralf Bartenschlager, and Matthew Bogyo"]},"title":[{"title":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19","title_sort":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19"}],"recId":"1766788823","id":{"doi":["10.1021/acsinfecdis.0c00815"],"eki":["1766788823"]},"relHost":[{"origin":[{"dateIssuedDisp":"2015-","dateIssuedKey":"2015","publisher":"ACS Publ.","publisherPlace":"Washington, DC"}],"id":{"zdb":["2806068-4"],"eki":["815910479"],"issn":["2373-8227"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 08.07.2021"],"name":{"displayForm":["American Chemical Society"]},"part":{"text":"7(2021), 6, Seite 1457-1468","pages":"1457-1468","year":"2021","volume":"7","issue":"6","extent":"12"},"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"American Chemical Society","role":"aut","roleDisplay":"VerfasserIn"}],"language":["eng"],"pubHistory":["1.2015 -"],"recId":"815910479","disp":"American Chemical SocietyACS infectious diseases","title":[{"title":"ACS infectious diseases","title_sort":"ACS infectious diseases"}]}],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"February 11, 2021"}],"note":["Gesehen am 13.08.2021"],"person":[{"roleDisplay":"VerfasserIn","family":"Steuten","given":"Kas","role":"aut","display":"Steuten, Kas"},{"given":"Heeyoung","role":"aut","display":"Kim, Heeyoung","family":"Kim","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Widen, John C.","given":"John C.","roleDisplay":"VerfasserIn","family":"Widen"},{"display":"Babin, Brett M.","role":"aut","given":"Brett M.","roleDisplay":"VerfasserIn","family":"Babin"},{"family":"Onguka","roleDisplay":"VerfasserIn","given":"Ouma","display":"Onguka, Ouma","role":"aut"},{"given":"Scott","role":"aut","display":"Lovell, Scott","roleDisplay":"VerfasserIn","family":"Lovell"},{"given":"Oguz","display":"Bolgi, Oguz","role":"aut","family":"Bolgi","roleDisplay":"VerfasserIn"},{"given":"Berati","display":"Cerikan, Berati","role":"aut","family":"Cerikan","roleDisplay":"VerfasserIn"},{"family":"Neufeldt","roleDisplay":"VerfasserIn","display":"Neufeldt, Christopher","role":"aut","given":"Christopher"},{"roleDisplay":"VerfasserIn","family":"Cortese","given":"Mirko","display":"Cortese, Mirko","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Muir","role":"aut","display":"Muir, Ryan K.","given":"Ryan K."},{"family":"Bennett","roleDisplay":"VerfasserIn","role":"aut","display":"Bennett, John M.","given":"John M."},{"family":"Geiss-Friedlander","roleDisplay":"VerfasserIn","given":"Ruth","display":"Geiss-Friedlander, Ruth","role":"aut"},{"family":"Peters","roleDisplay":"VerfasserIn","display":"Peters, Christoph","role":"aut","given":"Christoph"},{"given":"Ralf","display":"Bartenschlager, Ralf","role":"aut","roleDisplay":"VerfasserIn","family":"Bartenschlager"},{"roleDisplay":"VerfasserIn","family":"Bogyo","display":"Bogyo, Matthew","role":"aut","given":"Matthew"}],"physDesc":[{"extent":"12 S."}]} | ||
| SRT | |a STEUTENKASCHALLENGES1120 | ||